ASCO GU 2024

Is "more" always better?

Combination vs. monotherapy - a great new option for…

Cabo + IO: Interesting but not practice changing?!

Higher radiation is effective in high-risk PCA

BRCAaway - PARP combination study

What about the clinical benefit?

Relugolix combined with androgen signaling in real word…

Evaluating the recombination-repair mutations in…

Cognitive function in ART treatment

Further testing before olaparib combination

Combination of cabozantinib & checkpoint inhibitor

Long-term dose escalation - Therapy in high-risk…

Insights and news for mCRPC

Olaparib + Arbiraterone better compared to either alone

Localized PCa - news for radiotherapy and biochemical…

Therapy Intensification Still Neglected in mHSPC

Still a difficult time for androgenic inhibitors in…

Combination NHT + PARP makes sense

Quality of life under intensive therapy

Dose de-escalation in different ways

Enzalutamide therapy as option for biochemical…

Stockholm3 validated in multiethnic cohort

First positive study of IO therapy in mCRPC

Gleason 3+3 - cancer or not?

Kognitiv påverkan av abirateron och enzalutamid?

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Gleason 3+3 ska vi kalla de cancer eller inte?

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

BRCAAway - PARP hämmare, abiraterone eller i…

Kombination av cabozantinib och immunterapi

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

SEPTA calismasi: Stockholm3 un multietnik hasta…

Une période encore difficile pour les inhibiteurs…

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder…

HER2 and bladder cancer

Another success for an ICI?

EV as standard in 3rd line mUC

Highlights in bladder cancer at ASCO GU24

Update M1 urothelial cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Biomarker update

Update on EV-302

Adjuvant therapy in urothelial carcinoma : is the…

Perioperative adjuvant therapy in urothelial cancer

ASCO GU24 - Highlights in Bladder cancer

EV + Pembro new first-line standard in localized…

Should we start forgetting the Galsky Criteria in…

Pembrolizumab adjuvant in bladder cancer

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de…

Tratamiento adyuvante en cancer urotelial: ¿está…

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

No surprise with the QoL data

Trial updates at ASCO GU24: Are the follow-up data…

Subcutaneous vs. intravenous application: ready for…

Highlights in kidney cancer at ASCO GU24

Belzutifan: Updates on QoL

Long-term follow-up of first-line trials

Long-term outcome

Practice changing adjuvant therapy?!

Overall survival benefit - Pembro after surgery

Tumorburden and outcome

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Durable effects of Ipi-Nivo

Better QoL with Belzutifan

Perioperative treatment in renal cell carcinoma - did…

ASCO GU24 - Highlights in renal cell carcinoma

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Cabozantinib Plus Atezolizumab in Adrenocortical…

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24